Search

Displaying results 2531 - 2540 of 10000 in total
  1. Drug

    Anagrelide

    go.drugbank.com/drugs/DB00261
    ApprovedInvestigational

    [L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g. … Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms.

  2. Drug

    DL-Methylephedrine

    go.drugbank.com/drugs/DB11278
    Approved

    The abuse of methylephedrine-containing medications has been reported in Japan. Methylephedrine is not legally available in the United States, but has been identified in cases of drug abuse [L2836]. … Methylephedrine is a sympathomimetic amine that appears in various over-the-counter cough and cold medications throughout the world [L2838], [L2839], [L2840].

    Synonyms: (+/-)-N-methylephedrine, N-methylephedrine DL-form
  3. Drug

    2,2'-Dibenzothiazyl disulfide

    go.drugbank.com/drugs/DB14201
    Approved

    2,2'-Dibenzothiazyl disulfide is an accelerator used in the processing process for natural and synthetic rubber and plastic regeneration. It is also a known allergen and dermatological sensitizer.

  4. Drug

    Technetium Tc-99m nofetumomab merpentan

    go.drugbank.com/drugs/DB09336
    ApprovedWithdrawn

    It was after discontinued on August 13, 2013, but in the 2018 FDA submission list, it can be found as a substance type II (Drug substance) with an active status.[L1650, L1082] … [FDA label] Tc-99m nm was developed by Boehringer Ingelheim Pharma KG and FDA approved on September 14, 1992.

  5. Drug

    Coenzyme M

    go.drugbank.com/drugs/DB09110
    ApprovedInvestigational

    Coenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Cosibelimab

    go.drugbank.com/drugs/DB15770
    ApprovedInvestigational

    On December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the

  7. Drug

    Propoxycaine

    go.drugbank.com/drugs/DB09342
    Approved

    Although no longer available in the United States, this medication was used in combination with procaine to aid in anesthesia during dental procedures [L1592]. … Used in combination with procaine, it was the only dental local anesthetic available in cartridge form [L1592].

  8. Drug

    Hydromorphone

    go.drugbank.com/drugs/DB00327
    ApprovedIllicitInvestigational

    Structurally, hydromorphone derived from [morphine] in the modification of the hydroxyl group in the carbon 6 to a carbonyl and the absence of a double bond between the carbon 7 and 8. … [A176495] The first reported approved product containing hydromorphone in the form of hydromorphone hydrochloride was developed by Fresenius Kabi USA and FDA approved in 1984.[L5795]

  9. Drug

    Ibrexafungerp

    go.drugbank.com/drugs/DB12471
    Approved

    [A235414,L34349] Ibrexafungerp was granted FDA approval on 1 June 2021.[L34349] … [A235384,A235389] Similar to echinocandins, ibrexafungerp targets the fungal β-1,3-glucan synthase, which is not present in humans, limiting the chance of renal or hepatic toxicity.

  10. Target

    NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial

    go.drugbank.com/bio_entities/BE0000027
    TargetHumans

    May be the terminally assembled subunit of Complex I … Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis.

    Synonyms: Complex I-9kD